Myocardial extracellular signal regulatory kinases are activated by laser treatment

Journal of Cardiovascular Surgery

Volumn 44, Issue 1, 2003, Pages 1-7

  Liu, X H ^a,b   Grund, F ^a   Kanellopoulos, G K ^a,c   Kvernebo, K ^a   Ilebekk, A ^a  

^a ULLEVÅL UNIVERSITY HOSPITAL   (Norway)

^b CHINESE PLA GENERAL HOSPITAL   (China)

^c GLENFIELD HOSPITAL   (United Kingdom)

Author keywords

Angioplasty, transluminal, percutaneous coronary, methods; Coronary artery disease, surgery; Disease models, animal; Laser; Myocardial ischemia; Myocardial revascularization; Neovascularization, pathologic

Indexed keywords

FENTANYL; KETAMINE; MITOGEN ACTIVATED PROTEIN KINASE 1; MONOCLONAL ANTIBODY; MYELIN BASIC PROTEIN;

ANESTHESIA INDUCTION; ANGIOGENESIS; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; ENZYME ACTIVATION; ENZYME ACTIVITY; HEART LEFT VENTRICLE WALL; HEART MUSCLE BIOPSY; HEART MUSCLE INJURY; HEART MUSCLE REVASCULARIZATION; IN VITRO STUDY; ISCHEMIC HEART DISEASE; NONHUMAN; PROTEIN PHOSPHORYLATION; SWINE; TIME; TRANSLUMINAL CORONARY ANGIOPLASTY; WESTERN BLOTTING;

EID: 0037964119     PISSN: 00219509     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (30)

1. Kohmoto T, Argenziano M, Yamamoto N, Vliet KA, Gu A, DeRosa CM et al. Assessment of transmyocardial perfusion in alligator hearts. Circulation 1997;95:1585-91.
2. Schoebel FC, Frazier OH, Jessurun GA, De Jongste MJ, Kadipasaoglu KA, Jax TW et al. Refractory angina pectoris in end-stage coronary artery disease: evolving therapeutic concepts. Am Heart J 1997;134:587-602.
3. Sigel JE, Aabramovich CM, Lytle BW, Ratliff NB. Transmyocardial laser revascularization: three sequential autopsy cases. J Thorac Cardiovasc Surg 1998;115:1381-5.
4. Horvath KA, Mannting F, Cummings N, Shernan SK, Cohn LH. Transmyocardial laser revascularization: operative techniques and clinical results at two years. J Thorac Cardiovasc Surg 1996;111:1047-53.
5. Schofield PM, Sharples LD, Caine N, Burns S, Tait S, Wistow T et al. Transmyocardial laser revascularisation in patients with refractory angina: a randomised controlled trial. Lancet 1999; 353:519-24.
6. Allen KB, Dowling RD, Fudge TL, Schoettle GP, Selinger SL, Gangahar DM et al. Comparison of transmyocardial revascularization with medical therapy in patients with refractory angina. N Engl J Med 1999;341:1029-36.
7. Burkhoff D, Schmidt S, Sculman SP, Myers J, Resar J, Becker LC et al. Transmyocardial laser revascularization compared with continued medical therapy for treatment of refractory angina pectoris: a prospective randomised trial. Lancet 1999;354: 885-90.
8. Frazier OH, March RJ, Horvath KA. Transmyocardial revascularization with a carbon dioxide laser in patients with end-stage coronary artery disease. N Engl J Med 1999;341:1021-8.
9. 2 laser in patients with refractory angina pectoris. Clinical results from the Norwegian randomized trial. JACC 2000;35:1170-7.
10. Kim CB, Kesten R, Javier M, Hayase M, Walton AS, Billingham ME et al. Percutaneous method of laser transmyocardial revascularization. Cath Cardiovasc Diagn 1997;40:223-8.
11. Malekan R, Reynolds C, Narula N, Kelley ST, Suzuki Y, Bridges CR. Angiogenesis in transmyocardial laser revascularization. A nonspecific response to injury. Circulation 1998;98:II-62-6.
12. Zlotnick AY, Ahmad RM, Reul RM, Laurence RG, Aretz HT, Cohn LH. Neovascularization occurs at the site of closed laser channels after transmyocardial laser revascularization. Surg Forum 1996;67:286-7.
13. Yamamoto N, Kohmoto T, Gu A, DeRosa C, Smith CR, Burkhoff D. Angiogenesis is enhanced in ischemic canine myocardium by transmyocardial laser revascularization. JACC 1998;31: 1426-33.
14. Yamamoto N, Kohmoto T, Roethy W, Gu A, DeRosa C, Rabbani LE et al. Histologic evidence that fibroblast growth factor enhances the angiogenetic effects of transmyocardial laser revascularization. Basic Res Cardiol 2000;95:55-63.
15. Pages G, Milanini J, Richard DE, Berra E, Gothie E, Vinals F et al. Signaling angiogenesis via p42/p44 MAP kinase cascade. Ann N Y Acad Sci 2000;902:187-200.
16. Amemiya T, Sasamura H, Mifune M, Kitamura Y, Hirahashi J, Hayashi M et al. Vascular endothelial growth factor activates MAP kinase and enhances collagen synthesis in human mesangial cells. Kidney Int 1999;56:2055-63.
17. Milanini J, Vinals F, Pouyssegur J, Pages G. P42/p44 MAP kinase module plays a key role in the transcriptional regulation of the vascular endothelial growth factor gene in fibroblasts. J Biol Chem 1998;273:18165-72.
18. Ortega N, Hutchings H, Plouet J. Signalrelays in the VEGF system. Front Biosci 1999;4:D141-52.
19. Gonzalez FA, Seth A, Raden DL, Bowman DS, Fay FS, Davis RJ. Serum-induced translocation of mitogen-activated protein kinase to the cell surface ruffling membrane and the nucleus. J Cell Biol 1993;122:1089-101.
20. Derijard B, Raingeaud J, Barrett T, Wu IH, Han J, Ulevitch RJ et al. Independent human MAP-kinase signal transduction pathways defined by MEK and MKK isoforms. Science 1995;267: 682-5.
21. Han J, Lee JD, Bibbs L, Ulevitch RJ. A MAP kinase targeted by endotoxin and hyperosmolarity in mammalian cells. Science 1994;265:808-11.
22. Lai K, Wang H, Lee WS, Jain MK, Lee ME, Haber E. Mitogen-activated protein kinase phosphatase-1 in rat arterial smooth muscle cell proliferation. J Clin Invest 1996;98:1560-7.
23. Bogoyevitch MA, Gillespie-Brown J, Ketterman AJ, Fuller, SJ, Ben-Levy R, Ashworth A et al. Stimulation of the stress-activated mitogen-activated protein kinase subfamilies in perfused heart. p38/RK mitogen-activated protein kinases and c-Jun N-terminal kinases are activated by ischemia/reperfusion. Circ Res 1996;79:162-73.
24. Baines CP, Wang L, Cohen MV, Downey JM. Protein tyrosine kinase is downstream of protein kinase C for ischemic preconditioning's anti-infarct effect in the rabbit heart. J Mol Cell Cardiol 1998;30:383-92.
25. Katoch SS, Moreland RS. Agonist and membrane depolarization induced activation of MAP kinase in the swine carotid artery. Am J Physiol 1995;269:H222-9.
26. Vinals F, Pouyssegur J. Confluence of vascular endothelial cells induces cell cycle exit by inhibiting p42/p44 mitogen-activated protein kinase activity. Mol Cell Biol 1999;19:2763-72.
27. Redlitz A, Daum G, Sage EH. Angiostatin diminishes activation of the mitogen-activated protein kinases ERK-1 and ERK-2 in human dermal microvascular endothelial cells. J Vasc Res 1999;36:28-34.
28. Pages G, Berra E, Milanini J, Levy AP, Pouyssegur J. Stress-activated protein kinases (JNK and p38/HOG) are essential for vascular endothelial growth factor mRNA stability. J Biol Chem 2000;275:26484-91.
29. Gupta K, Kshirsager S, Li W, Gui L, Ramakrishnan S, Gupta P et al. VEGF prevents apoptosis of human microvascular endothelial cells via opposing effects on MAPK/ERK and SAPK/JNK signaling. Exp Cell Res 1999;247:495-504.
30. Huges GC, Lowe JE, Kypson AP, St Louis JD, Pippen AM, Peters KG et al. Neovascularization after transmyocardial laser revascularization in a model of chronic ischemia. Ann Thorac Surg 1998;66:2029-36.